Hanmi Pharm Signs $1.26B GLP2 Drug Tech Transfer Deal with Lilly - Maximizing Shareholder Value
Hanmi Pharm has signed a global (excluding South Korea) technology transfer agreement with Eli Lilly and Company for the long-acting GLP2 analogue biotherapy 'Sonefpeglutide (HM15912)'.
Total deal value is USD 1.26 billion (approx. KRW 1.8973 trillion, at exchange rate 1,505.80 KRW/USD), comprising a non-refundable upfront of USD 75 million (KRW 112.9 billion) and up to USD 1.185 billion (KRW 1.7844 trillion) in development, regulatory, and commercial milestones.
Milestone payments are conditional on achieving clinical, regulatory, and sales milestones. Hanmi will also receive tiered royalties on annual net sales.
Lilly obtains exclusive rights to develop, manufacture, and commercialize. No termination penalties apply to Hanmi.
This mega-deal with a top-tier global pharma company, without any equity dilution, amounts to ~30% of Hanmi's market cap (approx. KRW 6.22 trillion), representing an extremely positive event for shareholders.
[AI Summary]By securing this large-scale tech transfer with Lilly, Hanmi Pharm has de-risked the global commercialization of its GLP2 drug, while the non-refundable upfront and milestone structure ensures financial stability without diluting existing shareholders. The substantial cash inflow is expected to drive a strong positive impact on the stock price.
KOSPI Filing Information
Filing: Major Management Matters Related To Investment Decision (Execution Of Technology Transfer Agreement For Sonefpeglutide (Sonefpeglutide; LAPS GLP2 Agonist; HM15912))